1,742,636 research outputs found
6174
Get PDFVisualizing Kaprekar's Process:
1. Pick a 4-digit number, using at least two different digits.
2. Arrange the digits in descending and then in ascending order to get two four-digit numbers, adding leading zeros if necessary.
3. Subtract the smaller number from the bigger number.
4. Go back to step 2. and repeat.
The above process will always reach its fixed point, 6174. Thus spake D.R.Kaprekar (1905-1986) -- school teacher, recreational number theorist and Indian mathematician.
This is a graph of the process. Every four-digit number is a point on one of the circles. Every iteration outlined by Kaprekar is a path. His algorithm might be mechanical but the patterns emerging from it are anything but. At the center is the number 6174 (indicated by the red dot) to which all others are inexorably drawn. This plot itself was generated algorithmically using a combination of Python, TikZ, and LaTeX.Open Restriction set for Item 110774 on 2019-05-03T20:48:21Z with date null by [email protected] by Emilie Staubs ([email protected]) on 2019-05-03T20:50:02Z
No. of bitstreams: 2
Vaibhav Karve.pdf: 4916564 bytes, checksum: b935b208fd6c40099d0c05ae3d60f267 (MD5)
Vaibhav Karve.pdf: 52176455 bytes, checksum: 43322293dee4c0de2453bb1e4441d3a9 (MD5)Made available in DSpace on 2019-05-03T20:50:02Z (GMT). No. of bitstreams: 2
Vaibhav Karve.pdf: 4916564 bytes, checksum: b935b208fd6c40099d0c05ae3d60f267 (MD5)
Vaibhav Karve.pdf: 52176455 bytes, checksum: 43322293dee4c0de2453bb1e4441d3a9 (MD5)
Previous issue date: 2019Ope
[Carl Koch, Engine Drawing Card, Sketch No. 6174]
No full textThis engine drawing card was created for Carl Koch, Class 4-24 C. Section N-4C. Sketch 6174. Copy Spec. C-2415
6174: um problema com números de quatro algarismos
Get PDFAborda-se um problema clássico da chamada matemática recreativa. Uma operação definida para números com quatro algarismos, com pelo menos um distinto dos outros, é tal que, quando iterada, converge rapidamente para o número mágico 6174. Apresentamos uma descrição completa do número de iterações necessárias para se chegar ao 6174 e calcula-se o número esperado de iterações quando escolhemos arbitrariamente o número inicial. Referem-se algumas extensões deste problema clássic
DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1
No full textNew drugs for visceral leishmaniasis that are safe, low cost, and adapted to the field are urgently required. Despite concerted efforts over the last several years, the number of new chemical entities that are suitable for clinical development for the treatment of Leishmania remains low. Here, we describe the discovery and preclinical development of DNDI-6174, an inhibitor of Leishmania cytochrome bc1 complex activity that originated from a phenotypically identified pyrrolopyrimidine series. This compound fulfills all target candidate profile criteria required for progression into preclinical development. In addition to good metabolic stability and pharmacokinetic properties, DNDI-6174 demonstrates potent in vitro activity against a variety of Leishmania species and can reduce parasite burden in animal models of infection, with the potential to approach sterile cure. No major flags were identified in preliminary safety studies, including an exploratory 14-day toxicology study in the rat. DNDI-6174 is a cytochrome bc1 complex inhibitor with acceptable development properties to enter preclinical development for visceral leishmaniasis.No Full Tex
The mysterious beauty of 6174 / Siti Mariam Saad
Get PDFThe mysterious number 6174 is known as the Kaprekar’s constant. It was discovered by Indian mathematician D. R. Kaprekar in 1949. What makes this number so mysterious
ERI-effort and ERI-reward levels in dependence of gender (n = 6160) and profession (n = 6174).
No full textERI-effort and ERI-reward levels in dependence of gender (n = 6160) and profession (n = 6174).</p
Quantitative analysis of DNDI-6174 using UPLC-MS/MS : A preclinical target site pharmacokinetic study
No full textLeishmaniasis is a neglected parasitic infection that continues to pose a significant global health challenge, with currently limited effective treatment options. DNDI-6174 is a novel orally-active, investigational drug with antileishmanial properties. Herein, a novel ultra-high performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) method was developed and validated to quantify DNDI-6174 in relevant murine biomatrices, i.e., K2EDTA plasma and enzymatically-homogenized skin, spleen and liver to support the translational pharmacokinetic-pharmacodynamic model-informed drug development. The chromatographic system consisted of a gradient elution on a standard C18 column connected to a triple quadrupole MS, operating in positive ionization mode. Pre-processing of murine tissues with collagenase A led to a superior homogenization and analyte extraction compared to mechanical disruption. Human K2EDTA plasma served as a surrogate matrix, enabling accurate (bias between −12.0 % and 9.8 %) and precise (relative standard deviation (RSD) ≤ 12.5 %) quantification of DNDI-6174 in the various murine biomatrices. Sample processing with tert-methylbutyl ether resulted in a reproducible recovery between 70.0 % and 93.8 % (RSD ≤ 4.0 %) with an absolute matrix factor between 0.89 and 1.00 for all biomatrices. DNDI-6174 was stable under various conditions, including under tissue homogenization conditions, in all biomatrices investigated. This method was successfully applied in a translational study using a murine cutaneous leishmaniasis skin infection model to assess the target site pharmacokinetics of DNDI-6174, supporting its development as clinical candidate
DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1.
Get PDFNew drugs for visceral leishmaniasis that are safe, low cost, and adapted to the field are urgently required. Despite concerted efforts over the last several years, the number of new chemical entities that are suitable for clinical development for the treatment of Leishmania remains low. Here, we describe the discovery and preclinical development of DNDI-6174, an inhibitor of Leishmania cytochrome bc1 complex activity that originated from a phenotypically identified pyrrolopyrimidine series. This compound fulfills all target candidate profile criteria required for progression into preclinical development. In addition to good metabolic stability and pharmacokinetic properties, DNDI-6174 demonstrates potent in vitro activity against a variety of Leishmania species and can reduce parasite burden in animal models of infection, with the potential to approach sterile cure. No major flags were identified in preliminary safety studies, including an exploratory 14-day toxicology study in the rat. DNDI-6174 is a cytochrome bc1 complex inhibitor with acceptable development properties to enter preclinical development for visceral leishmaniasis
The prevalence of effort-reward imbalance ratio (ERI ratio > 1) in dependence of profession (N = 6174).
No full textThe prevalence of effort-reward imbalance ratio (ERI ratio > 1) in dependence of profession (N = 6174).</p
- …
